2m 2m 2m 2m 2m 2m 2m
AbbVie (ABBV)
NYSE
$233.79+$3.78 (+1.64%)
Price as of Jun 23, 2026 12:18 PM EDT- $406.4BMarket Cap
- 29.25%1-Year Change
- Drug Manufacturers - GeneralIndustry
AbbVie (ABBV)
$233.79+$3.78 (+1.64%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 61.2B +8.57% | 56.3B +3.71% | 54.3B -6.44% | 58.1B +3.30% | |
Cost of Revenue | 18.2B +7.69% | 16.9B -17.20% | 20.4B +17.23% | 17.4B -0.18% | |
Gross Profit | 43.0B +8.94% | 39.4B +16.30% | 33.9B -16.58% | 40.6B +4.87% | |
Sales and Marketing Expense | 14.0B -5.03% | 14.8B +14.61% | 12.9B -15.65% | 15.3B +23.57% | |
Research and Development Expense | -9.1B -28.89% | -12.8B +66.66% | -7.7B +17.90% | -6.5B -8.10% | |
Depreciation and Amortization Expense | 7.4B -3.21% | 7.6B -4.08% | 7.9B +3.34% | 7.7B -0.38% | |
Total Operating Expenses | 46.1B -2.36% | 47.2B +13.56% | 41.6B +4.07% | 39.9B +4.35% | |
Operating Profit | 15.1B +64.99% | 9.1B -28.38% | 12.8B -29.59% | 18.1B +1.08% | |
Interest Income | 266.0M -58.95% | 648.0M +20.00% | 540.0M +190.32% | 186.0M +376.92% | |
Interest Expense | -2.6B +21.62% | -2.2B +28.27% | -1.7B -17.61% | -2.0B -14.26% | |
Interest Income and Expense and Net | -2.4B +56.15% | -1.5B +32.17% | -1.1B -38.43% | -1.9B -20.77% | |
Total Nonoperating Income and Expense | -5.8B +78.80% | -3.2B -30.72% | -4.7B +91.05% | -2.4B -2.08% | |
Income before Taxes | 6.6B +77.53% | 3.7B -40.54% | 6.3B -53.62% | 13.5B +3.76% | |
Income Taxes | 2.4B +514.74% | -570.0M -141.39% | 1.4B -15.62% | 1.6B +13.33% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 4.2B -1.22% | 4.3B -12.03% | 4.9B -58.91% | 11.8B +2.55% | |
Net Income from Continuing Operations Applicable to Common | 6.6B +77.53% | 3.7B -40.54% | 6.3B -53.62% | 13.5B +3.76% | |
Basic EPS and Net Income | 2.37 -1.25% | 2.40 -12.09% | 2.73 -58.95% | 6.65 +2.62% | |
Diluted EPS and Net Income | 2.36 -1.26% | 2.39 -12.13% | 2.72 -58.97% | 6.63 +2.79% | |
Basic Weighted Average Shares | 1.8B 0.00% | 1.8B +0.06% | 1.8B -0.17% | 1.8B +0.06% | |
Diluted Weighted Average Shares | 1.8B 0.00% | 1.8B 0.00% | 1.8B -0.28% | 1.8B +0.06% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 5.2B -5.34% | 5.5B -56.89% | 12.8B +39.27% | 9.2B -5.59% | |
Short-Term Investments | 28.0M -9.68% | 31.0M +1,450.00% | 2.0M -92.86% | 28.0M -66.67% | |
Cash and Cash Equivalents and Short-Term Investments | 5.3B -5.36% | 5.6B -56.66% | 12.8B +38.87% | 9.2B -6.11% | |
Total Current Assets | 29.1B +13.60% | 25.6B -22.48% | 33.0B +15.95% | 28.5B +1.92% | |
Accumulated Depreciation | 7.9B +10.78% | 7.1B +7.33% | 6.6B +9.83% | 6.1B +7.73% | |
Property and Plant and Equipment and Net | 5.6B +9.62% | 5.1B +2.91% | 5.0B +1.09% | 4.9B -3.42% | |
Total Long-Term Assets | 10.7B +17.27% | 9.1B +7.39% | 8.5B +52.81% | 5.6B +14.07% | |
Total Assets | 134.0B -0.89% | 135.2B +0.33% | 134.7B -2.95% | 138.8B -5.27% | |
Income Taxes Payable | 2.4B -7.37% | 2.6B +32.12% | 2.0B -10.87% | 2.2B -27.22% | |
Total Short-Term Debt | 8.6B +25.73% | 6.8B -5.38% | 7.2B +73.86% | 4.1B -66.90% | |
Total Current Liabilities | 43.3B +11.72% | 38.7B +2.40% | 37.8B +28.11% | 29.5B -16.07% | |
Total Long-Term Debt | 58.9B -2.32% | 60.3B +15.61% | 52.2B -11.74% | 59.1B -7.87% | |
Total Long-Term Liabilities | 32.6B +8.10% | 30.1B -6.80% | 32.3B +5.45% | 30.7B +6.81% | |
Total Liabilities | 43.3B +11.72% | 38.7B +2.40% | 37.8B +28.11% | 29.5B -16.07% | |
Retained Earnings | -15.5B +96.11% | -7.9B +690.00% | -1.0B -120.90% | 4.8B +52.99% | |
Total Stockholders Equity | -3.3B -198.35% | 3.3B -67.91% | 10.4B -39.96% | 17.3B +11.98% | |
Total Shares Outstanding | 1.8B +0.39% | 1.8B +0.47% | 1.8B +0.51% | 1.8B +0.59% | |
Cash Flow | |||||
Cash from Operating Activities | 19.0B +1.19% | 18.8B -17.66% | 22.8B -8.44% | 24.9B +9.51% | |
Capital Expenditures | 1.2B +24.64% | 974.0M +25.35% | 777.0M +11.80% | 695.0M -11.69% | |
Cash from Investing Activities | -6.6B -68.09% | -20.8B +936.34% | -2.0B +222.47% | -623.0M -73.42% | |
Dividends Paid | 11.7B +5.73% | 11.0B +4.61% | 10.5B +4.94% | 10.0B +8.44% | |
Cash from Financing Activities | -12.7B +144.18% | -5.2B -69.74% | -17.2B -30.56% | -24.8B +30.27% | |
Financials Ratio | |||||
Gross Margin | 70.24% +0.35% | 69.99% +12.14% | 62.42% -10.84% | 70.00% +1.52% | |
Operating Margin | 24.65% +51.97% | 16.22% -30.94% | 23.49% -24.74% | 31.21% -2.16% | |
Return on Assets | 3.14% -0.94% | 3.17% -10.84% | 3.56% -57.14% | 8.30% +6.77% | |
Return on Equity | 15,367.27% +24,479.38% | 62.52% +77.51% | 35.22% -51.40% | 72.48% -10.57% | |
Revenue Growth | 8.57% +130.82% | 3.71% +157.67% | -6.44% -294.75% | 3.30% -85.44% | |
Current Ratio | 0.67 +1.68% | 0.66 -24.30% | 0.87 -9.50% | 0.96 +21.44% | |
Cash Ratio | 0.12 -15.29% | 0.14 -57.89% | 0.34 +8.70% | 0.31 +12.50% | |
Debt-to-Equity Ratio | -20.64 -202.22% | 20.19 +252.29% | 5.73 +56.32% | 3.67 -26.32% | |
Debt-to-Assets Ratio | 0.50 +1.43% | 0.50 +12.70% | 0.44 -3.29% | 0.46 -12.90% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow